Loading
A phase 2 trial of SYS6023 and KN026 in advanced solid tumours, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer is a phase 2 interventional study registered as NCT07597629 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 36 participants planned, started 2026-05-25 and due to reach its primary completion in 2027-11-30. Interventions recorded: SYS6023 and KN026.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Shares CSPC Pharmaceutical Group and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/